Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022
01/14/2022 - 07:06 AM
EASTWOOD, Australia , Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX, ASX: BNO), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, will ring the Nasdaq Closing Bell remotely from around the globe.
Dr Errol De Souza , Executive Chairman, will ring the Closing Bell alongside the Company's team in a virtual bell ringing ceremony.
When: FRIDAY, JANUARY 14, 2021 – 3:45 p.m. to 4:00 p.m. ET
Webcast :https://www.nasdaq.com/marketsite/bell-ringing-ceremony
Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/nasdaq .
For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq
Photos: To obtain a hi-resolution photograph of the Market Close, please go to https://www.nasdaq.com/marketsite/bell-ringing-ceremony and click on the market close of your choice.
FOR FURTHER INFORMATION PLEASE CONTACT:
About Bionomics Limited: Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada ) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn , on Twitter @Bionomics1 , or at www.bionomics.com.au .
About Nasdaq: Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn , on Twitter @Nasdaq , or at www.nasdaq.com .
https://www.prnewswire.com/news-releases/bionomics-limited-nasdaq-bnox-asx-bno-to-ring-the-nasdaq-stock-market-closing-bell-on-friday-january-14-2022-301461190.html
SOURCE Bionomics Limited
BNOX Rankings
#5138 Ranked by Stock Gains
BNOX Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Country
Australia
City
Thebarton
About BNOX
bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and alzheimer's disease. our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. we are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. this portfolio is fed by highly productive drug discovery platforms which includes multicore®, our proprietary chemistry capability. at the core of our business is strategic partnering. we partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. this means we can focus our strengths in innovative drug discovery to extract as many "shots on goal" from our diverse pipeline in the quest to create the world's new blockbuster drugs. we have a passion for
